Results 71 to 80 of about 3,462 (164)

Designing Multivalent and Multispecific Biologics

Annual Review of Chemical and Biomolecular Engineering
In the era of precision medicine, multivalent and multispecific therapeutics present a promising approach for targeted disease intervention. These therapeutics are designed to interact with multiple targets simultaneously, promising enhanced efficacy, reduced side effects, and resilience against drug resistance.
Jennifer J, Kang, Ayako, Ohoka, Casim A, Sarkar   +2 more
openaire   +2 more sources

Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipeline

Frontiers in Drug Discovery
Biologic therapies have reshaped treatment of atopic dermatitis, yet most available agents target only one cytokine or receptor and many patients still do not reach minimal disease activity.
Gili Amid-Toby, Omar Alani, Christopher G. Bunick   +2 more
doaj   +1 more source

Selectivity of OATs and OATPs for Endogenous Metabolites and Signaling Molecules <i>In Vivo</i>. [PDF]

ACS Omega
Nigam AK, Falah K, Momper JD, Nigam SK.
europepmc   +1 more source

Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology. [PDF]

Inflamm Bowel Dis
Colwill M, Patel K, Sebastian S, Din S, Honap S.   +4 more
europepmc   +1 more source

Evolution of bispecific and multispecific antibodies in cancer therapy. [PDF]

Lancet Reg Health Eur
Fontana E, Grochot R, Kotecki N, Doger B, Nannini S, de Miguel M.   +5 more
europepmc   +1 more source

Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers. [PDF]

Discov Oncol
Ardah MT, Abdulsahib WK, Abdulsahib WK, Jasim IK, Malathi H, Patro PS, Anand DA, Mukherjee G, Sinha A, Aminqulov S.   +9 more
europepmc   +1 more source

Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization. [PDF]

Sci Rep
Lee JH, Cho SY, Lee HE, Lee S.
europepmc   +1 more source

B cells enable autoreactive T cells to avoid suppression. [PDF]

Proc Natl Acad Sci U S A
Funsten M, de Pooter R, Varanasi V, Burrows M, Block K, Kuznetsov A, Serreze D, Huang H, Chervonsky A.   +8 more
europepmc   +1 more source

Pharmacological considerations for next-generation protein therapeutics in cardiovascular disease. [PDF]

J Pharmacol Exp Ther
Lin E, Momin N.
europepmc   +1 more source

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source